肺表皮样癌中的组织相容性位点抗原（HLA）
Histocompatibility locus antigens (HLA) in the epidermoid type of lung carcinoma.
作者信息
Prazák J, Mĕricka O, Chytrý J
机构信息
Institute of Haematology and Blood Transfusion, Prague, Czechoslovakia.
出版信息
J Cancer Res Clin Oncol. 1990;116(5):525-7. doi: 10.1007/BF01613006.
Abstract
HLA-A and B antigens were determined in a study of 162 patients (93 epidermoid type, 20 adenocarcinoma, 26 small-cell carcinoma and 23 undifferentiated types) with lung cancer. Differences between antigen frequencies in cancer and control populations were studied by chi 2Y analysis or Fisher's exact test. Survival data were analyzed using Cox's model for censored data. Cancer patients had a decreased frequency of the antigen HLA-B40 (chi 2Y = 14.15, P = 0.00018, Pc = 0.003, relative risk = 0.21). Patients with HLA-A10, A 11 and B27 had a shortened mean survival time. Patients with HLA-B12 had a prolonged survival time.
摘要
在一项针对162例肺癌患者（93例表皮样癌、20例腺癌、26例小细胞癌和23例未分化癌）的研究中，测定了HLA - A和B抗原。通过卡方检验或费舍尔精确检验研究癌症患者群体与对照群体中抗原频率的差异。使用Cox删失数据模型分析生存数据。癌症患者中抗原HLA - B40的频率降低（卡方检验=14.15，P = 0.00018，校正P = 0.003，相对风险=0.21）。携带HLA - A10、A11和B27的患者平均生存时间缩短。携带HLA - B12的患者生存时间延长。
相似文献
1
Histocompatibility locus antigens (HLA) in the epidermoid type of lung carcinoma.肺表皮样癌中的组织相容性位点抗原（HLA）
J Cancer Res Clin Oncol. 1990;116(5):525-7. doi: 10.1007/BF01613006.
2
Frequency changes in HLA-I alleles: A marker to guide immunotherapy in lung adenocarcinoma patients and its relationship with tumor mutational burden and PD-L1 expression.HLA-I 等位基因频率变化：指导肺腺癌患者免疫治疗的标志物及其与肿瘤突变负担和 PD-L1 表达的关系。
Thorac Cancer. 2023 Jul;14(20):1932-1940. doi: 10.1111/1759-7714.14939. Epub 2023 May 28.
3
Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2.对 HLA-A2 相关的日本非小细胞肺癌患者的细胞毒性 T 淋巴细胞及 Fas/FasL 的分析
J Cancer Res Clin Oncol. 2002 Nov;128(11):581-8. doi: 10.1007/s00432-002-0381-y. Epub 2002 Oct 25.
4
Association of HLA class I and II genes with cutaneous leishmaniasis: a case control study from Sri Lanka and a systematic review.人类白细胞抗原I类和II类基因与皮肤利什曼病的关联：来自斯里兰卡的病例对照研究及系统评价
BMC Infect Dis. 2016 Jun 14;16:292. doi: 10.1186/s12879-016-1626-8.
5
Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?循环 ABCC3 转运蛋白自身抗体是否为肺癌的潜在生物标志物？
J Cancer Res Clin Oncol. 2012 Oct;138(10):1737-42. doi: 10.1007/s00432-012-1260-9. Epub 2012 Jun 15.
6
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
7
HLA antigens and bronchogenic carcinoma.人类白细胞抗原与支气管源性癌
Neoplasma. 1989;36(5):599-602.
8
Role of human leukocyte antigen in anti-epileptic drugs-induced Stevens-Johnson Syndrome/toxic epidermal necrolysis: A meta-analysis.人类白细胞抗原在抗癫痫药物诱导的史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症中的作用：一项荟萃分析。
Seizure. 2022 Nov;102:36-50. doi: 10.1016/j.seizure.2022.09.011. Epub 2022 Sep 17.
9
HLA B27 antigen in Middle Eastern and Arab countries: systematic review of the strength of association with axial spondyloarthritis and methodological gaps.中东和阿拉伯国家的人类白细胞抗原B27抗原：与轴性脊柱关节炎关联强度的系统评价及方法学差距
BMC Musculoskelet Disord. 2017 Jun 29;18(1):280. doi: 10.1186/s12891-017-1639-5.
10
The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis.表皮生长因子受体（EGF-R）表达在肺癌患者生存中的作用：一项荟萃分析的系统评价
Eur Respir J. 2002 Oct;20(4):975-81. doi: 10.1183/09031936.02.00296502.
引用本文的文献
1
HLA alleles and lung cancer in a Turkish population.土耳其人群中的HLA等位基因与肺癌
Ann Saudi Med. 2004 Mar-Apr;24(2):106-11. doi: 10.5144/0256-4947.2004.106.
本文引用的文献
1
HLA antigens and primary bronchial carcinoma.
Cancer. 1982 Jun 15;49(12):2485-8. doi: 10.1002/1097-0142(19820615)49:12<2485::aid-cncr2820491212>3.0.co;2-c.
2
Association between HLA-Bw44 and small-cell carcinoma of the lung.
N Engl J Med. 1982 Oct 21;307(17):1087. doi: 10.1056/NEJM198210213071723.
3
The World Health Organization. Histological typing of lung tumours.世界卫生组织。肺肿瘤组织学分类。
Neoplasma. 1982;29(1):111-23.
4
HLA frequency and prognosis in lung cancer.肺癌中的人类白细胞抗原频率与预后
Br J Cancer. 1981 May;43(5):610-4. doi: 10.1038/bjc.1981.90.
5
Histocompatibility antigens in small cell carcinoma of the lung.肺小细胞癌中的组织相容性抗原。
Cancer. 1984 Dec 15;54(12):2943-5. doi: 10.1002/1097-0142(19841215)54:12<2943::aid-cncr2820541221>3.0.co;2-#.
6
Serotyping for homotransplantation. 18. Refinement of microdroplet lymphocyte cytotoxicity test.同种移植的血清分型。18. 微滴淋巴细胞细胞毒性试验的改进。
Transplantation. 1968 Nov;6(8):913-27. doi: 10.1097/00007890-196811000-00006.
7
HL-A antigens and disease. Statistical and genetical considerations.组织相容性白细胞抗原与疾病。统计学及遗传学考量。
Tissue Antigens. 1974;4(2):95-105. doi: 10.1111/j.1399-0039.1974.tb00230.x.
8
HLA and survival in lung cancer.人类白细胞抗原与肺癌患者的生存率
Clin Immunol Immunopathol. 1987 Oct;45(1):55-62. doi: 10.1016/0090-1229(87)90111-5.
9
Prolonged survival in bronchogenic carcinoma associated with HL-A antigens W-19 and HL-A5: a preliminary report.与HL - A抗原W - 19和HL - A5相关的支气管源性癌患者的长期存活：初步报告
J Natl Cancer Inst. 1975 Jun;54(6):1283-6. doi: 10.1093/jnci/54.6.1283.
10
A note of relative risks.
Tissue Antigens. 1977 Jan;9(1):59-61.
Zotero 插件